Benzinga | Sep 27, 2021 08:16AM EDT

Canaccord Genuity Initiates Coverage On Pacific Biosciences with Buy Rating, Announces Price Target of $45

Canaccord Genuity analyst Kyle Mikson initiates coverage on Pacific Biosciences (NASDAQ:PACB) with a Buy rating and announces Price Target of $45.